1. Scrip
  2. >>R&D
  3. >>Trial Results

AstraZeneca Hopes Danicopan Interim Data Will Prove Sufficient For NDA Filing

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Danicopan seen as potential add-on therapy for paroxysmal nocturnal hemoglobinuria patients getting suboptimal results from Soliris or Ultomiris therapy. AstraZeneca will investigate filing for approval on 12-week data.

Hemolysis
AstraZeneca thinks danicopan can provided added benefit for some PNH patients • Source: Shutterstock

AstraZeneca PLC hopes interim data from a Phase III trial of danicopan will be sufficient to file the novel factor D inhibitor for approval to treat extravascular hemolysis (EVH) in patients who take Ultomiris or Soliris for paroxysmal nocturnal hemoglobinuria (PNH). The biopharma reported on 16 September that 12-week data from the ALPHA trial shows that danicopan met the primary endpoint of change in hemoglobin levels from baseline as well as key secondary endpoints.

Obtaining approval of danicopan could be a key factor in maintaining dominance in the complement inhibitor space – AstraZeneca became...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D